Kalytera Therapeutics, Inc - KALY

Kalytera Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, develops cannabinoid medicines for a range of unmet medical needs. It is developing cannabidiol formulations to prevent and treat acute graft versus host diseases. The company is also developing K-1032, a prodrug for the treatment of chronic inflammatory skin diseases, such as acne vulgaris; K-1012, a prodrug for the treatment of adult respiratory distress syndrome; K-1022, a prodrug to treat ulcerative colitis; and K-1052, a prodrug for the treatment of sepsis-induced acute renal failure and traumatic brain injury. Kalytera Therapeutics, Inc. was founded in 2014 and is headquartered in Novato, California.